BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 34933203)

  • 1. Druggable genetic targets in endometrial cancer
    Lehrer S; Rheinstein PH
    Cancer Treat Res Commun; 2022; 30():100502. PubMed ID: 34933203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-risk endometrial cancer proteomic profiling reveals that FBXW7 mutation alters L1CAM and TGM2 protein levels.
    Urick ME; Yu EJ; Bell DW
    Cancer; 2021 Aug; 127(16):2905-2915. PubMed ID: 33872388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.
    Van Gool IC; Stelloo E; Nout RA; Nijman HW; Edmondson RJ; Church DN; MacKay HJ; Leary A; Powell ME; Mileshkin L; Creutzberg CL; Smit VT; Bosse T
    Mod Pathol; 2016 Feb; 29(2):174-81. PubMed ID: 26743472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteomic profiling of FBXW7-mutant serous endometrial cancer cells reveals upregulation of PADI2, a potential therapeutic target.
    Urick ME; Bell DW
    Cancer Med; 2020 Jun; 9(11):3863-3874. PubMed ID: 32248654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L1CAM is an independent predictor of poor survival in endometrial cancer - An analysis of The Cancer Genome Atlas (TCGA).
    Dellinger TH; Smith DD; Ouyang C; Warden CD; Williams JC; Han ES
    Gynecol Oncol; 2016 May; 141(2):336-340. PubMed ID: 26861585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L1 Cell Adhesion Molecule as a Predictor of Disease-Specific Survival and Patterns of Relapse in Endometrial Cancer.
    Pasanen A; Tuomi T; Isola J; Staff S; Bützow R; Loukovaara M
    Int J Gynecol Cancer; 2016 Oct; 26(8):1465-71. PubMed ID: 27648714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L1CAM Expression is Related to Non-Endometrioid Histology, and Prognostic for Poor Outcome in Endometrioid Endometrial Carcinoma.
    Geels YP; Pijnenborg JM; Gordon BB; Fogel M; Altevogt P; Masadah R; Bulten J; van Kempen LC; Massuger LF
    Pathol Oncol Res; 2016 Oct; 22(4):863-8. PubMed ID: 26891628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L1CAM expression associates with poor outcome in endometrioid, but not in clear cell ovarian carcinoma.
    Soovares P; Pasanen A; Bützow R; Lassus H
    Gynecol Oncol; 2017 Sep; 146(3):615-622. PubMed ID: 28625395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.
    Edmondson RJ; Crosbie EJ; Nickkho-Amiry M; Kaufmann A; Stelloo E; Nijman HW; Leary A; Auguste A; Mileshkin L; Pollock P; MacKay HJ; Powell ME; Bosse T; Creutzberg CL; Kitchener HC
    Gynecol Oncol; 2017 Aug; 146(2):327-333. PubMed ID: 28511869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FBXW7, L1CAM, and TGM2 in endometrial cancer.
    Lehrer S; Rheinstein PH
    Cancer; 2021 Nov; 127(21):4103-4104. PubMed ID: 34324708
    [No Abstract]   [Full Text] [Related]  

  • 11. Reply to FBXW7, L1CAM, and TGM2 in endometrial cancer.
    Urick ME; Yu EJ; Bell DW
    Cancer; 2021 Nov; 127(21):4105. PubMed ID: 34324196
    [No Abstract]   [Full Text] [Related]  

  • 12. Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study.
    Visser NCM; van der Putten LJM; van Egerschot A; Van de Vijver KK; Santacana M; Bronsert P; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Krakstad C; Tangen IL; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Hausnerova J; Snijders MPLM; van den Berg-van Erp S; Matias-Guiu X; Trovik J; Amant F; Massuger LFAG; Bulten J; Pijnenborg JMA
    Hum Pathol; 2019 Jul; 89():90-98. PubMed ID: 31054899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancer-testis (CT-X) antigens.
    Schirmer U; Fiegl H; Pfeifer M; Zeimet AG; Müller-Holzner E; Bode PK; Tischler V; Altevogt P
    BMC Cancer; 2013 Mar; 13():156. PubMed ID: 23530769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers.
    Schultheis AM; Martelotto LG; De Filippo MR; Piscuglio S; Ng CK; Hussein YR; Reis-Filho JS; Soslow RA; Weigelt B
    Int J Gynecol Pathol; 2016 Jul; 35(4):289-300. PubMed ID: 26556035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. L1CAM expression in endometrial carcinomas: an ENITEC collaboration study.
    van der Putten LJ; Visser NC; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Trovik J; Kopperud RK; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Jandakova E; Snijders MP; van den Berg-van Erp S; Matias-Guiu X; Salvesen HB; Amant F; Massuger LF; Pijnenborg JM
    Br J Cancer; 2016 Sep; 115(6):716-24. PubMed ID: 27505134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The genetic landscape of endometrial clear cell carcinomas.
    DeLair DF; Burke KA; Selenica P; Lim RS; Scott SN; Middha S; Mohanty AS; Cheng DT; Berger MF; Soslow RA; Weigelt B
    J Pathol; 2017 Oct; 243(2):230-241. PubMed ID: 28718916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L1CAM and HER2 Expression in Early Endometrioid Uterine Cancer.
    Abdel Azim S; Sprung S; Mutz-Dehbalaie I; Fessler S; Zeimet AG; Marth C
    Int J Gynecol Pathol; 2017 Jul; 36(4):356-363. PubMed ID: 28221216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas.
    Huszar M; Pfeifer M; Schirmer U; Kiefel H; Konecny GE; Ben-Arie A; Edler L; Münch M; Müller-Holzner E; Jerabek-Klestil S; Abdel-Azim S; Marth C; Zeimet AG; Altevogt P; Fogel M
    J Pathol; 2010 Apr; 220(5):551-61. PubMed ID: 20077528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L1CAM expression as a predictor of platinum response in high-risk endometrial carcinoma.
    Romani C; Capoferri D; Reijnen C; Lonardi S; Ravaggi A; Ratti M; Bugatti M; Zanotti L; Tognon G; Sartori E; Odicino F; Calza S; Pijnenborg JMA; Bignotti E
    Int J Cancer; 2022 Aug; 151(4):637-648. PubMed ID: 35429348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification.
    Karnezis AN; Leung S; Magrill J; McConechy MK; Yang W; Chow C; Kobel M; Lee CH; Huntsman DG; Talhouk A; Kommoss F; Gilks CB; McAlpine JN
    J Pathol Clin Res; 2017 Oct; 3(4):279-293. PubMed ID: 29085668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.